Long-Term Outcomes after Imatinib Mesylate Discontinuation in Chronic Myeloid Leukemia Patients with Undetectable Minimal Residual Disease

By  

Acta Haematologica, Vol. 135, Iss. 3, 2015-11 ,pp. : 133-139

Karger

Access to resources Recommend Favorite

Chronic phase chronic myeloid leukemia patients who failed interferon alpha and switched to imatinib: Long‐term 9‐year follow‐up of 134 patients

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 5, 2015-05 ,pp. : E95-E96

John Wiley & Sons Inc

Access to resources Recommend Favorite

Continuing Imatinib Treatment for Chronic Myeloid Leukemia Patients Who Had Serious Adverse Events at the Onset of Therapy

By  

Acta Haematologica, Vol. 137, Iss. 3, 2017-04 ,pp. : 158-162

Karger

Access to resources Recommend Favorite

Evaluation of Long-Term Outcomes, Cytogenetic and Molecular Responses with Imatinib Mesylate in Early and Late Chronic-Phase Chronic Myeloid Leukemia: A Report from a Single Institute

By  

Acta Haematologica, Vol. 128, Iss. 4, 2012-08 ,pp. : 223-232

Karger

Access to resources Recommend Favorite

Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib

By Goldberg Stuart L.   Chen Lei   Guerin Annie   Macalalad Alexander R.   Liu Nathan   Kaminsky Michael   Ericson Solveig G.   Wu Eric Q.  

Current Medical Research and Opinion, Vol. 29, Iss. 9, 2013-09 ,pp. : 1075-1082

Informa Healthcare

Access to resources Recommend Favorite